dr. sharman on remaining challenges with btk inhibitors in cll
Published 4 years ago • 219 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
1:03
dr. sharman on the challenges of adjusting treatment based on mrd status in cll
-
1:05
dr. sharman on entospletinib in patients with cll
-
0:52
dr jeff sharman: cost of therapy is a major challenge in cll
-
2:37
jeffrey sharman, md, explains how we should be thinking about btk inhibitors in the treatment of cll
-
1:47
dr. sharman on the potential approval of acalabrutinib in cll
-
1:09
dr. sharman on unmet clinical needs in high-risk relapsed/refractory cll
-
2:46
challenges in the use of btk inhibitors for cll
-
0:49
front-line treatment options for cll | dr. jeff sharman | oncology brothers #2023
-
1:22
dr. ghosh on unanswered questions with btk inhibitors in cll/sll
-
2:09
dr. sharman on the phase iii results of the genuine study in cll
-
3:25
btk inhibitors in cll: treatment selection
-
0:57
dr. byrd on alacabrutinib's mechanism of action in cll
-
2:05
dr. sharman on the results of the genuine trial in cll
-
1:28
dr. ma on the utility of btk inhibitors in relapsed/refractory cll
-
2:13
dr. tam discusses btk inhibition in cll
-
0:58
what is cll, and does everyone really needs treatment? | dr. jeff sharman | oncology brothers #2023
-
4:26
btk inhibitors in relapsed/refractory cll
-
1:25:33
customizing care in cll with btk inhibitors
-
5:06
evolution of btk inhibitors in cll